Device profile of the SAPIEN 3 transcatheter heart valve in low-risk patients with aortic stenosis: overview of its safety and efficacy.
Alberto Alperi GarciaJules MesnierVassili PanagidesJosep Rodés-CabauPublished in: Expert review of medical devices (2021)
The approval of THV systems for use in low-risk patients has been a significant step forward in expanding current TAVR indications. Along with procedural refinement and growing operator experience, device iterations implemented in new-generation THV systems have played a vital role in the successful spread of TAVR. The availability of SAPIEN 3 represented an inflection point, as it allows for a predictable positioning and safer navigability while dramatically decreasing the rate of residual paravalvular leakage compared to previous balloon-expandable systems. However, some unresolved issues remain like the relatively high rates of conduction disturbances and the uncertainty about valve performance in the long-term. Future studies are warranted.
Keyphrases
- aortic stenosis
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation
- ejection fraction
- aortic valve
- aortic valve replacement
- end stage renal disease
- left ventricular
- chronic kidney disease
- newly diagnosed
- heart failure
- current status
- peritoneal dialysis
- atrial fibrillation
- drug administration